OptimizeRx Announces Leadership Changes and Board Expansion
Market News

OptimizeRx Announces Leadership Changes and Board Expansion

OptimizeRx Corporation (OPRX) has released an update to notify the public and investors about its officers.

Gus Halas retired as Chairperson of the Board of OptimizeRx Corporation, and Lynn O’Connor Vos was appointed in his place and to several committee roles effective January 24, 2024. The Board expanded to seven members, adding Catherine M. Klema as a director, who will also serve on the Audit and Compensation Committees. Klema will receive compensation as per the company’s non-employee director program, including cash retainers and an equity grant.

For further insights into OPRX corporate activity, check out TipRanks’ Insiders Trading Activity page.

Related Articles
Brian AndersonIs OPRX a Buy, Before Earnings?
TheFlyOptimizeRx continues to expand strategic relationship with pharma client
TheFlyOptimizeRx price target lowered to $14 from $17 at RBC Capital
Go Ad-Free with Our App